Churg-Strauss syndrome: Difference between revisions
| Line 29: | Line 29: | ||
==Management== | ==Management== | ||
===Initiation Therapy=== | |||
* | *[[Prednisone]] 0.5-1.5 mg/kg/day | ||
*Cyclophosphamide | |||
===Maintenance Therapy=== | |||
*Azathioprine | |||
*Methotrexate | |||
*Leflunomide | |||
*Inhaled glucocorticoids | |||
==Disposition== | ==Disposition== | ||
Revision as of 11:19, 7 February 2016
Background
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic sinusitis, asthma, and peripheral eosinophilia
- Vasculitis of small and medium sized vessels
- Lung and skin are most commonly involved
Clinical Features
Classically develops in three sequential phases:
- Prodrome
- Atopic diseases, allergic rhinitis, and asthma
- Eosinophilic phase
- Multiorgan involvement, particularly lung and GI tract
- Caused by eosinophilic infiltration into these organs
- Vasculitic phase
- Life threatening vasculitis associated with vascular and extravascular granulomatosis
- May present with nonspecific signs such as fever, weight loss, malaise
Differential Diagnosis
- Aspirin-exacerbated respiratory disease
- Chronic eosinophilic pneumonia
- Allergic bronchopulmonary aspergillosis
- Hypereosinophilic syndrome
- Other vasculitides
Diagnosis
- Typically a clinical diagnosis
- Labs with elevated eosinophils, ESR, CRP, ANCA
- CXR with transient, patchy opacities
Management
Initiation Therapy
- Prednisone 0.5-1.5 mg/kg/day
- Cyclophosphamide
Maintenance Therapy
- Azathioprine
- Methotrexate
- Leflunomide
- Inhaled glucocorticoids
Disposition
- Refer to rheumatology
See Also
External Links
References
<UpToDate>
